Physician profile
Henry Johnson
NPI 1295218782
$1,793.62
in general payments reported to CMS, 2019-2025
18 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $376 · 2023: $391 · 2024: $146 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.92 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $317.86 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $227.64 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $197.30 | 2021-2022 | |
| Axsome Therapeutics, INC. | $130.94 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $130.50 | 2022-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $107.22 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Indivior INC. | $46.00 | 2021-2022 | |
| Abbvie INC. | $40.41 | 2021 | |
| Noven Therapeutics, LLC | $37.59 | 2022-2023 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $37.14 | 2025 | Rexulti |
| Eisai INC. | $23.08 | 2021-2022 | |
| Corium, LLC | $21.12 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $20.48 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $19.79 | 2025 | Cobenfy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $18.81 | 2022 | |
| Braeburn INC. | $15.67 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $14.15 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.